Glaxosmithkline receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
GSK plc DRC (GSK)
GSK plc DRC stock price live, this page displays NYSE GSK stock exchange data. View the GSK premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the GSK plc DRC real time stock price chart below.
What Is the GSK plc DRC Stock Price Today?
The GSK plc DRC stock price today is 48,32.
What Is the Stock Symbol for GSK plc DRC?
The stock symbol for GSK plc DRC is "GSK."
What Stock Exchange Does GSK plc DRC Trade On?
GSK plc DRC is listed and trades on the NYSE stock exchange.
Is GSK plc DRC a Good Stock to Buy?
Determining whether GSK plc DRC—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the GSK quote. (ISIN: US37733W2044)
What Is the GSK plc DRC Stock Price Today?
The GSK plc DRC stock price today is 48,32.
What Is the Stock Symbol for GSK plc DRC?
The stock symbol for GSK plc DRC is "GSK."
What Stock Exchange Does GSK plc DRC Trade On?
GSK plc DRC is listed and trades on the NYSE stock exchange.
Is GSK plc DRC a Good Stock to Buy?
Determining whether GSK plc DRC—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the GSK quote. (ISIN: US37733W2044)
48.32
-0.42(-0.86%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
48.03
49.11
52 wk Range
45.81
61.70
GSK is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
48.0349.11
52 wk Range
45.8161.70
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
GSK Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
60.51
Upside
+25.23%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
2 analysts have revised their earnings downwards for the upcoming period
- Glaxosmithkline receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
- Glaxosmithkline receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
4 Buy
4 Hold
1 Sell
Ratings:
9 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 60.51
(+25.23% Upside)
GSK plc DRC Earnings Call Summary for Q3/2026
- GSK posted Q3 2026 adjusted EPS of $1.45 vs. $1.32 est. and revenue of $11.83B vs. $11.73B est.; shares fell 6.28% premarket to $47.74.
- Specialty medicines grew 15% driving growth; company raised 2026 restructuring charges to GBP 1B under Accelerate Growth program.
- Currency headwinds now expected to cut sales 1% and operating profit 3%; interest expense forecast at GBP 700M-750M including Nuvalent costs.
- GSK reaffirmed 2026 guidance with sales and core operating profit in upper half of range; margin expected to exceed 31% at constant FX.
- Pipeline accelerated with 22 phase III starts planned for 2026 vs. 10 originally; Hibsago hepatitis B approval and Cabenuva readout expected 2027.
Last Updated: 2026/10/28, 15:30
Read Full TranscriptEarnings
Latest Release
Oct 28, 2026
EPS / Forecast
0,73 / 0,51
Revenue / Forecast
11,79B / 8,39B
Compare GSK to Peers and Sector
Metrics to compare | GSK | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGSKPeersSector | |
|---|---|---|---|---|
P/E Ratio | 15.1x | 22.0x | −0.3x | |
PEG Ratio | 0.36 | 0.36 | 0.00 | |
Price/Book | 4.1x | 5.2x | 2.6x | |
Price / LTM Sales | 2.2x | 2.5x | 2.9x | |
Upside (Analyst Target) | 24.1% | 15.4% | 60.1% | |
Fair Value Upside | Unlock | 11.2% | 8.3% | Unlock |
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases; and strategic research collaboration with Engitix Ltd. to identify and validate novel therapeutic targets driving liver fibrosis regression. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. The company was founded in 1715 and is headquartered in London, United Kingdom.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the GSK plc DRC (GSK) Stock Price Today?
The GSK plc DRC stock price today is 48,32 USD.
What Stock Exchange Does GSK plc DRC Trade On?
GSK plc DRC is listed and trades on the New York Stock Exchange.
What Is the Stock Symbol for GSK plc DRC?
The stock symbol for GSK plc DRC is "GSK."
Does GSK plc DRC Pay Dividends? What’s The Current Dividend Yield?
The GSK plc DRC dividend yield is 3,6%%.
What Is the GSK plc DRC Market Cap?
As of today, GSK plc DRC market cap is 96,59B USD.
What Is GSK plc DRC's Earnings Per Share (TTM)?
The GSK plc DRC EPS (TTM) is 1,59.
When Is the Next GSK plc DRC Earnings Date?
GSK plc DRC will release its next earnings report on Feb 03, 2027.
From a Technical Analysis Perspective, Is GSK a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has GSK plc DRC Stock Split?
GSK plc DRC has split 5 times.
How Many Employees Does GSK plc DRC Have?
GSK plc DRC has 66841 employees.
What is the current trading status of GSK plc DRC (GSK)?
As of Oct 29, 2026, GSK plc DRC (GSK) is trading at a price of 48,32 USD, with a previous close of 48,74 USD. The stock has fluctuated within a day range of 48,03 USD to 49,11 USD, while its 52-week range spans from 45,81 USD to 61,70 USD.
What Is GSK plc DRC (GSK) Price Target According to Analysts?
The average 12-month price target for GSK plc DRC is 60,51 USD, with a high estimate of 70 USD and a low estimate of 49 USD. 4 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +25,23% Upside potential.
What Is the GSK Premarket Price?
GSK's last pre-market stock price is 48,20 USD. The pre-market share volume is 418 250,00, and the stock has decreased by -0,54, or -1,11%.
What Is the GSK After Hours Price?
GSK's last after hours stock price is 48,55 USD, the stock has decreased by -0,19, or -0,39%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.